# Clinical outcomes of the EyeWatch system: three-year results

**Authors:** Constance Liegl, Sarah Hundertmark, Frank G. Holz, Karl Mercieca

PMC · DOI: 10.1007/s00417-025-06942-2 · Graefe's Archive for Clinical and Experimental Ophthalmology · 2025-08-16

## TL;DR

A three-year study shows the EyeWatch system effectively lowers eye pressure in glaucoma patients, with lasting results and fewer medications needed.

## Contribution

This is the first study to report three-year clinical outcomes of the EyeWatch system for glaucoma management.

## Key findings

- Eye pressure dropped from 34.6 mmHg pre-surgery to 13.6 mmHg after three years.
- All patients maintained eye pressure below 21 mmHg without needing frequent device adjustments after the first year.
- MRI exposure caused temporary eye pressure spikes, highlighting the need for monitoring in magnetic environments.

## Abstract

The EyeWatch™ System (EWS) is an adjustable glaucoma drainage device that allows non-invasive postoperative intraocular pressure (IOP) control.Early studies have shown promising short- and mid-term results with EWS in managing refractory glaucoma.

The EyeWatch™ System (EWS) is an adjustable glaucoma drainage device that allows non-invasive postoperative intraocular pressure (IOP) control.

Early studies have shown promising short- and mid-term results with EWS in managing refractory glaucoma.

This study presents the first three-year clinical outcomes of EWS implantation, showing a sustained IOP reduction from a preoperative mean of 34.6 mmHg to 13.6 mmHg, with all patients achieving IOP levels below 21 mmHg and a significant decrease in medication burden.Most device adjustments occurred within the first postoperative year, after which IOP remained stable without further intervention.A transient IOP elevation following MRI underscores the importance of monitoring EWS patients in the context of magnetic exposure.

This study presents the first three-year clinical outcomes of EWS implantation, showing a sustained IOP reduction from a preoperative mean of 34.6 mmHg to 13.6 mmHg, with all patients achieving IOP levels below 21 mmHg and a significant decrease in medication burden.

Most device adjustments occurred within the first postoperative year, after which IOP remained stable without further intervention.

A transient IOP elevation following MRI underscores the importance of monitoring EWS patients in the context of magnetic exposure.

## Linked entities

- **Diseases:** glaucoma (MONDO:0005041)

## Full-text entities

- **Genes:** EWSR1 (EWS RNA binding protein 1) [NCBI Gene 2130] {aka EWS, EWS-FLI1}
- **Diseases:** hyphema (MESH:D006988), IOP spike (MESH:D031261), trauma (MESH:D014947), primary open-angle glaucoma (MESH:D005902), vitreous hemorrhage (MESH:D014823), GDD (MESH:D009471), glaucoma (MESH:D005901)
- **Chemicals:** acetazolamide (MESH:D000086), EyePlate (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12886197/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12886197/full.md

---
Source: https://tomesphere.com/paper/PMC12886197